Rabbani S N, Patel Y C
Fraser Laboratories, McGill University, Montreal, Quebec, Canada.
Endocrinology. 1990 Apr;126(4):2054-61. doi: 10.1210/endo-126-4-2054.
Mammalian prosomatostatin (pro-S) undergoes extensive processing at the C-terminal segment where the somatostatin-like biological activities (S-14 and S-28) reside. The recent discovery of pro-S-(1-10) (antrin) as a prominent mature product in the stomach suggests that pro-S may also be processed at the N-terminus. In the present study we have developed an antibody directed against the N-terminal segment of pro-S-(1-10) capable of detecting peptides extended at the C-terminus of pro-S-(1-10) to characterize N-terminal processing of rat pro-S. Specifically, we have 1) examined the relative abundance of pro-S-(1-10)-like immunoactivity [pro-S-(1-10)] in different somatostatin tissues as an index of tissue-specific N-terminal processing, 2) compared the concentrations of pro-S N- and C-terminal immunoreactive peptides, 3) used HPLC and region-specific RIAs directed against both the N- and C-terminal segments of pro-S to identify and characterize novel N-terminal peptides, 4) studied the tissue distribution and release of the N-terminal peptides; and 5) characterized and quantified a 7-kDa molecule equivalent to pro-S without the C-terminal S-28 sequence. Acetic acid (1 M)-pepstatin extracts of hypothalamus, cerebral cortex, antrum, jejunal mucosa, and pancreas were fractionated by reverse phase and gel permeation HPLCs. Whole tissue extracts as well as the column effluent were monitored by region-specific RIAs using antibodies against pro-S-(1-10), S-28-(1-12), and S-14. Other than the pancreas, all S-producing tissues were rich in pro-S-(1-10) LI. Its concentration was 1- to 4-fold lower than those of S-14 LI and S-28-(1-12) LI. Tissue pro-S-(1-10) LI was heterogeneous, consisting of at least eight molecular forms with respective mol wt of 1,000 (1 kDa), 1,500 (1.5 kDa), 2,500 (2.5 kDa), 3,500 (3.5 kDa), 4,500 (4.5 kDa), 7,000 (7 kDa), 8,000 (8 kDa), and 10,000 (10 kDa). Based on the simultaneous presence or absence of C-terminal immunoreactivity, the 10-kDa form corresponded to pro-S, 8 kDa to pro-S-(1-76), and 7 kDa to pro-S without the S-28 sequence. The predominant N-terminal forms corresponded to 1 kDa [pro-S-(1-10)] and 7 kDa. The 1-, 1.5-, 2.5-, and 7-kDa forms were identified as secretion products in portal blood or in medium from cultured 1027 B2 islet somatostatin cells.(ABSTRACT TRUNCATED AT 400 WORDS)
哺乳动物前生长抑素(pro-S)在其C末端片段会经历广泛加工,生长抑素样生物活性物质(S-14和S-28)就存在于该片段。最近发现胃中一种主要的成熟产物前生长抑素-(1-10)(安曲肽)表明,前生长抑素也可能在N末端进行加工。在本研究中,我们制备了一种针对前生长抑素-(1-10)N末端片段的抗体,该抗体能够检测在前生长抑素-(1-10)C末端延伸的肽段,以表征大鼠前生长抑素的N末端加工过程。具体而言,我们:1)检测了不同生长抑素组织中前生长抑素-(1-10)样免疫活性物质[前生长抑素-(1-10)]的相对丰度,作为组织特异性N末端加工的指标;2)比较了前生长抑素N末端和C末端免疫反应性肽段的浓度;3)使用高效液相色谱(HPLC)和针对前生长抑素N末端和C末端片段的区域特异性放射免疫分析(RIA)来鉴定和表征新的N末端肽段;4)研究了N末端肽段的组织分布和释放情况;5)表征并定量了一种7 kDa的分子,其等同于不含C末端S-28序列的前生长抑素。下丘脑、大脑皮层、胃窦、空肠黏膜和胰腺的1 M醋酸-胃蛋白酶抑制剂提取物通过反相和凝胶渗透HPLC进行分离。使用针对前生长抑素-(1-10)、S-28-(1-12)和S-14的抗体,通过区域特异性RIA对全组织提取物以及柱流出物进行监测。除胰腺外,所有产生生长抑素的组织中前生长抑素-(1-10)LI含量丰富。其浓度比S-14 LI和S-28-(1-12)LI低1至4倍。组织前生长抑素-(1-10)LI具有异质性,至少由八种分子形式组成,各自的分子量分别为1000(1 kDa)、1500(1.5 kDa)、2500(2.5 kDa)、3500(3.5 kDa)、4500(4.5 kDa)、7000(7 kDa)、8000(8 kDa)和10000(10 kDa)。根据C末端免疫反应性的有无,10 kDa形式对应前生长抑素,8 kDa对应前生长抑素-(1-76),7 kDa对应不含S-28序列的前生长抑素。主要的N末端形式对应1 kDa[前生长抑素-(1-10)]和7 kDa。1 kDa、1.5 kDa、2.5 kDa和7 kDa形式被鉴定为门静脉血或培养的1027 B2胰岛生长抑素细胞培养基中的分泌产物。(摘要截短于400字)